CliffBio
small molecule

ACETAMINOPHEN

ACETAMINOPHEN

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyFresenius Kabi →View the full company profile on CliffBio

Drug detail

Brand nameACETAMINOPHEN
Active ingredientACETAMINOPHEN
Strength1GM/100ML (10MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2015
Marketing statusRX

Listed patents

PatentExpiresType
8741959April 2030product

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ACETAMINOPHEN patent cliff — loss of exclusivity April 2030 | CliffBio